The effects of a number of cytotoxic drugs are influenced by cellular reduction/oxidation (redox) state. In the present study, we attempt to explore if dicoumarol, an inhibitor of NADPH: quinone oxidoreductase (NQO1), alters the cellular redox state and how this alteration affects the redox-related apoptosis. Flow cytometry was used to assess the reactive oxygen species (ROS) level and apoptotic rates of HeLa cells treated with arsenic trioxide (As 2 O 3 ) alone or in combination with natural anthraquinone emodin and dicoumarol or plus N-acetyl-cysteine. Western blot, immunofluorescence, electrophoretic mobility shift assay and luciferase assay were used to detect Nuclear Factor kappa B (NF-κB) activation. The results showed that dicoumarol synergized with emodin to sensitize HeLa cells to As 2 O 3 -induced apoptosis through raising the ROS level. More notably, this enhanced susceptibility was associated with a ROS-mediated inhibition of NF-κB activation in which the combinative treatment with dicoumarol prevented NF-κB from binding to target DNA. It was suggested that dicoumarol in combination with anthraquinones might be a novel strategy to expand the chemotherapeutic spectrum of As 2 O 3 by means of interfering the cellular redox state.
Cellular reduction/oxidation (redox) state was found to play an important role in regulation of cell proliferation, differentiation and apoptosis [1, 2] . Researches in the past decade showed that the chemotherapeutic effects of a number of cytotoxic drugs are influenced by the cellular redox state. Arsenic trioxide (As 2 O 3 ), as a novel chemotherapeutic agent treating acute promyelocytic leukemia (APL), induces apoptosis of leukemia cells with dependence on the cellular redox state [3, 4] . Redox state is balanced by the relative quantities of the oxidative and reductive substances. Reactive oxygen species (ROS) in the cells, including superoxide anion (O 2 -•), hydroxyl radical (•OH), hydrogen peroxide (H 2 O 2 ) and 1 O 2 , are the major components of the endogenous oxidants. The majority of them are generated during electron transport on the mitochondrial respiration chain, at the ubiquinone sites between complex I and complex III [5] . In our previous studies, we found that the inherent ROS level was closely correlated to the apoptotic susceptibility in different cell types to As 2 O 3 and an elevation of ROS level by a naphthoquinone (2,3-dimethoxy-1,4-naphthoquinone, DMNQ) could sensitize the cells to As 2 O 3 -induced apoptosis [6] . It allows an assumption that elevating cellular ROS level might be an approach to enhance the anticancer effects of arsenic and other chemotherapeutic agents. We then screened out a number of natural anthraquinones similar to ubiquinone and DMNQ in molecular structure. We have evidenced that emodin, one of the natural anthraquinones, did enhance As 2 O 3 -rendered cytotoxicity in tumor cells through increasing the generation of intracellular ROS [7] .
Quinones in the cells may be changed between the forms of oxidation and reduction due to the adjustment of physiological redox regulatory system [8] . Therefore we attempt to find an agent that remains exogenenous quinones in their oxidative form and then to see how it affects the redox-related apopotosis. In the present study, dicoumarol is selected as an auxiliary agent to anthraquinone emodin. The role of dicoumarol in As 2 O 3 -induced apoptosis and its possible signaling pathway is investigated.
Materials and Methods

Reagents
As 2 O 3 , emodin, dicoumarol, N-acetyl-cystein (NAC), 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) and tumor necrosis factor-α (TNF-α) were purchased from Sigma, and AnnexinV-FITC/PI kit from BD Pharmingen Inc. Stock solutions for the various drugs were prepared by first dissolving the agents in vehicles described below and then diluting to the proper concentration with PBS. As 2 O 3 were solubilized in NaOH at 10 mM, emodin in DMSO and dicoumarol in pyridine at 100 mM.
Cell culture
HeLa, human cervix epithelioid line cells, obtained from American Type Culture Collection (ATCC) were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco BRL) supplemented with 100 U/ml penicillin, 100 mg/L streptomycin and 10% fetal bovine serum at 37°C in a humidified incubator with 5% CO 2 .
Groups
Group "C", untreated control; Group "A", treated with 2 µM As 2 O 3 ; Group "AE", treated with 2 µM As 2 O 3 and 10 µM emodin;
Group "AED", treated with 2 µM As 2 O 3 , 10 µM emodin, and 20 µM dicoumarol;
Group "AEDN", treated with 2 µM As 2 O 3 , 10 µM emodin, 20 µM dicoumarol, and 2 mM NAC;
Group "AEN", treated with 2 µM As 2 O 3 , 10 µM emodin, and 2 mM NAC.
The addition of "T" before group name meant TNF-α was applied in that group.
Cell viability assay
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) staining. Briefly, cells were cultured in 96 well plates at a density of 1×10 5 cells/ml and treated with different doses of dicoumarol or other drug combination for 48 h, then 10 µl MTT solution (5 g/L) per well was added and incubated for another 4 h at 37 °C. Absorbance at 490 nm on a microplate reader (Bio-Tek Instruments) is directly proportional to the number of living cells in culture.
ROS detection
DCFH-DA was used as ROS capture in the cells. It is cleaved intracellularly by nonspecific esterases to form DCFH, which is further oxidized by ROS to form the fluorescent compound DCF. HeLa cells were exposed to DCFH-DA and the variety of drugs for 15 min. NAC, when used, was pre-incubated for 2 h with the cells. After being washed once with ice-cold PBS, cells were harvested and kept on ice for an immediate detection by flow cytometry. The average DCF intensity reflected ROS level.
Apoptosis assay
Cells were cultured in 6-well plates in the density of 1×10 5 cells/ml and treated with different drugs for 3 days. Cells were then collected and stained with annexin V-FITC and PI according to the manufacture's instruction (BD Pharmingen), and then analyzed by flow cytometry.
Western blot detection for Iκ κ κ κ κBα α α α α degradation Cells were starved overnight in serum-free medium. After being pre-treated with the drugs for 30min and stimulated with TNF-α for 1h where it was used, cells were lysed in 100 µl of sample solution (625 mM Tris, 10% SDS, 25% glycerol, 100 mM dithiothreitol) and underwent a sonication followed by a heat denaturation. Protein extracts were separated on 12% SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was subsequently incubated with a rabbit anti-IκBα antibody (cell signaling) and horseradish peroxidaseconjugated goat anti-rabbit immunoglobulin (IgG) respectively for proper time before detected by an enhanced chemiluminescence system. Re-probing the membrane with an antibody against β-actin was performed to serve as a loading control.
Cytochemistry for NF-κ κ κ κ κB p50 subunit translocation
After starvation and treatments with the drugs as described in methods of Western blot detection, cells were first fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100, then incubated with a rabbit anti-NF-κB p50 antibody (Upstate, USA) for overnight at 4 °C followed by FITC-conjugated goat anti-rabbit IgG for 1 h. Cells were examined by using a confocal microscope (Zeiss).
Luciferase assay
Plasmid expression vector pNF-κB-luc contains sequence for NF-κB-directed Luciferase reporter, which has the binding site of NF-κB. When activated, NF-κB binds to this sequence and initiate the expression of luciferase. The extent of NF-κB activation represented by relative luciferase activity (RLA) was acquired by normalization of transfection variation with the activity of renilla, whose DNA was co-transfected.
Cells were transiently transfected with pNF-κB-luc and pRenilla by using LipofectAmine TM 2000 reagent (Invitrogen TM Life Technologies) according to manufacturer's instruction. After about 40 h, cells were exposed to the variety of agents for about 5 h after an overnight starvation in serum-free medium, and then cells lysates were assayed for the expression of luciferase and renilla on aluminometer Junior LB 9509 (Berthold).
Electrophoretic mobility shift assay
Cells were treated as above. Nuclear extracts were prepared as described previously [7, 9] . DNA probe (Promega) containing NF-κB-binding sequence was labeled with 32 P according to the manufacture's instruction. After incubation of the 32 P-probe with nuclear extracts protein for 20 min, DNA-protein complex was formed if the nuclear extracts contained the activated NF-κB. DNA-protein complex and free DNA probe were then separated on 4% polyacrylamide gels. Dried gel was exposed to a PhopoImage and visualized on a scanner (Fujifilm-5000).
Results
Low dose of dicoumarol has little effect on cell viability
After HeLa cells were treated with different doses of dicoumarol for 48 h, cell viability decreased in a dosedependent manner compared with untreated group. We noticed that dicoumarol at 20 µM caused little effect on cell viability. With increasing of doses of treatment, the number of the viable cells decreased, and cell number reduced apparently in 100 µM-treated group (Fig. 1) . Therefore 20 µM of dicoumarol was selected as the dose used for the combination with the other drugs since dicoumarol alone at this dose caused no discernable effect on cell viability.
Dicoumarol augments emodin/As 2 O 3 -caused elevation of ROS level
Cells treated by 10 µM of emodin alone caused a mild elevation of ROS level, compared with untreated cells. Co-treatment with 10 µM of emodin and 2 µM of As 2 O 3 caused a higher ROS level although As 2 O 3 alone caused little change. Dicoumarol at the dose of 20 µM dramatically augmented this ROS elevation led by As 2 O 3 /emodin combination. Pre-treatment of cells with 2 mM NAC for 2 h partially or completely abolished two or three drugs combination-stimulated ROS elevation (Fig. 2) .
Fig. 1 Cell viability assay (MTT)
Cells were treated with dicoumarol at the different doses for 48 h before incubated with MTT for an additional 4 h. Cell viability, reflected by 490 nm absorbance, was decreased in a dose-dependent way, whereas 20 mM did not affect cell viability.
Fig. 2 Flow cytometric assay for ROS level
Cells were exposed to the drugs for 15 min. DCFH-DA was incubated with cells simultaneously to capture ROS. Cellular ROS level was higher in AE-treated samples than that was in A-treated ones, and AED further augmented ROS elevation. NAC attenuated AE-or AED-potentiated ROS elevation.
Dicoumarol synergizes with emodin to sensitize HeLa cells to As 2 O 3 -induced apoptosis
It is one of the early features of cells undergoing apoptosis that phosphatidylserine (PS) translocates from the inner to the outer leaflet of the plasma membrane. AnnexinV can bind to exposed PS. The results of AnnexinV/PI double staining flow cytometry showed that 10 µM of emodin didn't cause appreciable effect on HeLa cells. When cells were treated with 2 µM of As 2 O 3 plus 10 µM of emodin, apoptotic rates increased significantly to about 37%, compared with 21% caused by As 2 O 3 alone. It was further increased to about 53% after co-administration of two drugs with dicoumarol, although 20 µM of dicoumarol alone did not significantly enhance As 2 O 3 -induced apoptosis. On the other hand, pre-incubating cells with antioxidant NAC partially blocked apoptosis caused by two-or three-drug. These results indicated that when emodin sensitized tumor cells to As 2 O 3 , dicoumarol enhanced this effect. The synergistic effect of dicoumarol was dependent on ROS (Fig. 3) .
Dicoumarol leads a potentiated inhibition of NF-κ κ κ κ κB activation
It has been reported that redox-sensitive transcription factor NF-κB is involved in cell survival/apoptosis. In this process, degradation of inhibitory subunit IκBα and Western blot for Iκ κ κ κ κBα α α α α
The degradation of IκBα with a variety of drug treatments was investigated without (A) or with TNF-α(B). Results showed that the extent of IκBα degradation was not altered by indicated drugs (A). TNF-α induced IκBα degradation, but the variety of drug treatments did not change the IκBα degradation induced by TNF-α (B).
Fig. 6
Luciferase assay for NF-κ κ κ κ κB activation Cells were starved overnight for 40 h post-transfection followed by the pretreatment with the drugs for 30 min. TNF-α was added for additional 4 h where it was used. Results showed that NF-κB activation RLA was slightly increased in As 2 O 3 -treated cells, and this was inhibited in two and three drug combinations. TNF-α-stimulated NF-κB activation was inhibited by As 2 O 3 plus emodin and significantly further inhibited by two drugs plus dicoumarol. NAC abolished emodin-or emodin plus dicoumarol-rendered inhibition of NF-κB activation.
Fig. 5 Immunofluorescence for p50 translocation
The intracellular translocation of p50 induced by indicated drugs were analyzed by the indirect immunofluorescence method. p50 mainly located in cytoplasm in untreated cells and translocated into the nucleus upon TNF-α stimulation. Various drugs did not affect this translocation induced by TNF-α.
translocation of the liberated NF-κB subunits p50 and p65 to the nucleus precede p50/p65 binding to the target genes and promoting gene transcription. In order to explore if the activation of NF-κB was altered in emodin plus dicoumarol-rendered enhancement of apoptosis, we examined these events respectively, including IκBα degradation, p50 translocation, NF-κB binding to their target DNA and NF-κB-driven reporter gene transcription. Our result of Western blot showed that the different treatments, i.e. As 2 O 3 alone, As 2 O 3 combined with emodin or plus dicoumarol, seemed not change the basal level of IκBα [ Fig. 4(A) ]. We then used TNF-α as a stimulator and investigated the effects of the drugs on TNF-α -stimulated NF-κB activation. Result showed that these drugs conferred no appreciable influence on TNF-α-stimulated IκBα degradation [ Fig. 4(B) ]. Immunofluorescence showed that TNF-α-stimulated p50 translocation to the nucleus was not altered by the drug treatments either (Fig. 5) . However, in luciferase assay, the basal level of NF-κB activation, indicated by relative luciferase activity (RLA), increased slightly in As 2 O 3 -treated cells. After co-treating cells with As 2 O 3 and emodin, this increase was inhibited. Addition of dicoumarol further potentiated the suppressive effect of emodin. This trend became significantly obvious when TNF-α was used as an inducer for NF-κB activation. NAC could antagonize the inhibitory effects that two-drug or three-drug treatment caused (Fig. 6 ). As demonstrated in EMSA, binding of NF-κB to DNA probe induced by TNF-α was inhibited by emodin in combination with As 2 O 3 , and this inhibition was further potentiated by dicoumarol. Again these inhibitions were reversed by NAC (Fig. 7) .
Discussion
The metabolism of quinones in the cell, probably existed in forms of reduction or oxidation, is regulated by NADPH dehydrogenase that uses NADPH or NADH as electron donor. Also termed "NADPH: quinone oxidoreductase (NQO1)", NADPH dehydrogenase is important to maintain the normal cellular functions, mainly through its impact on cellular redox state [8, [10] [11] [12] . In order to protect exogenous quinones emodin from being reduced by NQO1 and to ensure it taking on effect in form of oxidation, we combined dicoumarol, an inhibitor of NQO1, with emodin. Had been used clinically to inhibit blood coagulation for a long time, dicoumarol was first reported to inhibit enzymatic activity of NQO1 in 1970s and further proved by research in the subsequent years. Now it has been used extensively as an inhibitor of NQO1 in the relevant research, though the way it inhibits the enzyme activity is not clear [10] [11] [12] .
Our results showed that both ROS level and the rate of apoptosis became apparently higher after cells were treated with arsenic in combination with emodin or emodin plus dicoumarol, compared with arsenic alone or arsenic plus emodin, respectively. NAC attenuated these effects. It indicated that dicoumarol could potentiate the effect of emodin, sensitizing HeLa cells to As 2 O 3 -induced apoptosis through raising ROS level. ROS is known to induce expression of NQO1, which, in turn, reduces ROS by its oxidoreductase activity through a negative feedback loop [12] . Hence the inhibition of NQO1 activity by dicoumarol not only elevates ROS level indirectly, but also increases oxidative quinones directly, which will result in a more oxidative state in the cells. This change in redox state will be sensed by redox-sensitive transcription factors, prevailing the other redox-sensitive signaling molecules, since these transcription factors directly regulate gene expression and ultimately alter the balance of cell survival and death [13, 14] .
Several transcription factors have been reported to be redox-regulated, including NF-κB, activator protein (AP-1) and hypoxia-inducible factor (Hif-1α). NF-κB is the most important transcription factors responsive directly to oxidative stress and plays a pivotal role in cell growth, differentiation, apoptosis, inflammation and so on [1, 15] . Inactive NF-κB is composed of the subunit p50, p65 and inhibitory subunit IκBα, and sequestered in the cytoplasm. The various stimuli will induce phosphorylation (serines 32 and 36), ubiquitination and degradation of IκBα. Activated NF-κB, consisting of the p65/50 dimers, then translocated into the nucleus and transcriptionally activates target genes by first binding to the responsive elements in the DNA called κB motifs. In some system the NF-κB complex is liberated upon phosphorylation of tyrosine instead of serines, where IκBα degradation is not involved [1, 15, 16] .
In this study, we found that the relatively more oxidative state caused by co-administration of dicoumarol with emodin could enhance As 2 O 3 -rendered cytotoxicity on tumor cells. In order to explore the precise mechanism and to elucidate whether and how NF-κB participated in this process, we first investigated the degradation of IκBα with a variety of drug treatments, but we did not see alteration in the extent of IκBα degradation. We then suspected if the drugs caused an inhibition, rather than a stimulation, on the IκBα degradation, which was not subject to observation at the basal level. TNF-α was thereby used as a classic activator for NF-κB [17] [18] [19] . The results demonstrated that the variety of drug treatments did not virtually change either the IκBα degradation or the subsequent nuclear translocation of p50 induced by TNF-α. However, two lines of evidence indicated that ROS elevation led to NF-κB inhibition. First, TNF-α-induced luciferase reporter expression activity was inhibited by two or three drug combinations. Co-treatment of As 2 O 3 with emodin and dicoumarol, in parallel with a gradual ROS elevation, resulted in a gradually potentiated inhibition on TNF-α-induced NF-κB activation, as RLA appeared TAED<TAE <TA. Second, as EMSA revealed, this inhibited activation was attributed to an inhibited binding of NF-κB to its target DNA. The antioxidant NAC abolished two or three drug-rendered inhibition of NF-κB binding and activity, which further confirmed the relationship between ROS elevation and NF-κB inhibition. It is known that NF-κB is activated in response to the oxidative stress, which means that ROS may induce activation of NF-κB by causing IκBα degradation and nuclear translocation of p50/p65 [20] . However it is also noticed that the binding of p50/p65 to their targets requires a reductive environment in the nucleus [21, 22] , since the redox-sensitive cysteine residues within the DNA-binding region of NF-κB may be oxidized, which then leads its failure to bind to target genes [23] . In current study, with the treatments of emodin and dicoumarol in combination with As 2 O 3 , ROS leads to an NF-κB inhibition specific to its capabilities of binding to the target DNA and consequently promoting their transcription, whereas IκBα degradation and p50 translocation are not affected. This can be elucidated with the notion that an extreme oxidative bias brought by the three-drug combination may result in a condition unfavorable to NF-κB binding.
Despite that activation of NF-κB occurs in apoptosis induced by various stimuli, most of researchers tend to believe that the role of NF-κB is anti-apoptosis, because NF-κB promotes expression of genes encoding the proteins resistant to apoptosis, such as Bcl-2 and the newly reported survivin [24, 25] . Our previous work also showed that inactivation of NF-κB increased cellular sensitivity to As 2 O 3 alone and two drugs combination [7] , indicating that NF-κB activation played an anti-apoptotic role in this specific cellular context. Exposure of cells to As 2 O 3 may trigger not only pro-apoptotic signaling pathway, probably also pro-survival pathway, which are reflected by a tiny increase of NF-κB-driven reporter activity. Oxidative conditions resulted from co-treatment of dicoumarol and emodin significantly suppressed NF-κB activity in response to As 2 O 3 . This suppression of anti-apoptotic forces may lead up to a shift of the survival/death control, and finally potentiate As 2 O 3 -triggered apoptosis.
We have previously confirmed that an enhancement of arsenic efficacy by emodin is non-toxic to non-tumor cells and with low systemic effect [7, 26] . As emodin is derived from plants and dicoumarol is traditionally used in clinical remedy, given all, the present study suggests that ROS generators may serve as the chemotherapeutic auxiliary to expand the spectrums of As 2 O 3 and other cytotoxic drugs as well as to control their dosages when 
